Pulmonary Arterial Hypertension
About
-
Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.
Load morePulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.
PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.
Load Less
-
Brett Wanamaker, Thomas Cascino, Vallerie V McLaughlin, et alArrhythmia & Electrophysiology Review 2018;7(1):43–8.DOI: https://doi.org/10.15420/aer.2018.3.2
-
Saumil R Shah, Sergio Waxman, William H Gaasch, et alUS Cardiology Review 2017;11(2):72–4.DOI: https://doi.org/10.15420/ucs.2017:9:2
-
Julia Sikorska, James UprichardEuropean Cardiology Review 2017;12(1):40–5.DOI: https://doi.org/10.15420/ecr.2017:11:2
-
Jelena Celutkiene, Mindaugas Balčiūnas, Denis Kablučko, et alCardiac Failure Review 3(1):56–61.DOI: https://doi.org/10.15420/cfr.2016:23:2
